Most cited papers from PEG-Bio Biopharm

PEG-Bio Biopharm

What are the most cited papers from PEG-Bio Biopharm?

The most cited paper from PEG-Bio Biopharm is "A Peptide-Based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Coronavirus Disease 2019" (Xue-Fei Cai et al., 2020), with 175 citations. Next come "Site‐specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity" (59) and "A Peptide-based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Corona Virus Disease 2019 (COVID-19)" (40).

Published TypeFieldAccess

Showing 13 of 13 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	A Peptide-Based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Coronavirus Disease 2019 Xue-Fei Cai et al. · The Journal of Infectious Diseases Open access	4 May 2020	175
2	Site‐specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity Nian Gong, Ai‐Niu Ma, Lijie Zhang et al. · British Journal of Pharmacology Open access	19 Jan 2011	59
3	A Peptide-based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Corona Virus Disease 2019 (COVID-19) Xue-Fei Cai et al. · medRxiv PreprintOpen access	25 Feb 2020	40
4	Preparation and purification of monoclonal antibodies against chloramphenicol Yi Yu, Zhuhuan Wang, Min Li et al. · Cytotechnology Open access	10 Dec 2011	12
5	Safety, tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator PB-201 and its effects on the glucose excursion profile in drug-naïve Chinese patients with type 2 diabetes: a randomised controlled, crossover, single-centre phase 1 trial Dongyang Liu, Ying Du, Xueting Yao et al. · EClinicalMedicine Open access	5 Nov 2021	11
6	Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study Linong Ji et al. · Diabetologia Open access	9 Mar 2021	11
7	A multicentre, randomized, double‐blind, parallel, active‐ and placebo‐controlled Phase 3 clinical study of the glucokinase activator PB ‐201 in treatment‐naive patients with type 2 diabetes mellitus: A study protocol Ying Du, Leili Gao, Xinhua Xiao et al. · Diabetes Obesity and Metabolism	30 Oct 2022	7
8	Population Pharmacokinetic/Pharmacodynamic Analysis of the Glucokinase Activator PB201 in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus: Facilitating the Clinical Development of PB201 in China Ling Song, Fangrui Cao, Shu Niu et al. · Clinical Pharmacokinetics	20 Nov 2023	5
9	Development of a PBPK model to quantitatively understand absorption and disposition mechanism and support future clinical trials for PB‐201 Miao Zhang, Zihan Lei, Ziheng Yu et al. · CPT Pharmacometrics & Systems Pharmacology Open access	20 Apr 2023	5
10	Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers Hong Cui, Caiyun Zhao, Yuan Lv et al. · European Journal of Drug Metabolism and Pharmacokinetics	12 Feb 2021	5
11	Screening technologies for recombinant antibody libraries Mieko Kato, Yoshiro Hanyu · Medical Research Archives Open access	6 Nov 2015	5
12	Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 study Xiaoling Cai, Linong Ji, Mingxia Yuan et al. · The Lancet Regional Health - Western Pacific Open access	Oct 2024	0
13	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Glucokinase Activator PB-201 and its Effects on the Glucose Excursion Profile in Drug-Naive Chinese Patients with Type 2 Diabetes: A Randomised Controlled, Crossover Trial Dongyang Liu, Ying Du, Xueting Yao et al. · SSRN Electronic Journal PreprintOpen access	2021	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.